<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Accuray Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/accuray-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 Fourth Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:41:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91177</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported favorable fourth-quarter 2011 results. Earnings per share came in at $3.75, beating the Zacks Consensus Estimate of $3.34 and the year-ago earnings of $3.02. Net income climbed 24.8% year over year to $151.2 million. Fourth Quarter Review Revenues increased 28% year over year to $496.8 million, beating the Zacks Consensus Estimate of $483 million. Instruments and accessories revenues were $196 million in the quarter, up 30% year over year. Worldwide procedures increased 27%. The company posted total systems revenue of $225 million in the quarter, up 27%. Services/Training revenues were $75 million in the quarter, up 24% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Agreement – Estimate Revisions Estimates for fiscal 2012 demonstrate an upward trend among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Squarely Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562</link>
		<comments>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562#comments</comments>
		<pubDate>Wed, 25 Jan 2012 17:58:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90562</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2011 earnings per share of $3.75 and $12.32, respectively, beating the Zacks Consensus Estimates of $3.34 and $11.89, respectively, while surpassing the corresponding year-ago results of $3.02 and $9.47. Revenues Intuitive reported revenues of $496.8 million and $1,757.3 million for the fourth quarter and fiscal 2011, respectively, up 28% and 24% year over year. The results beat the Zacks Consensus Estimates of $483 million and $1,741 million, respectively. On a segment basis, the company reported revenues from instruments and accessories of $196 million, up 30% year over year, in the fourth quarter. The growth was driven by a 27% year-over-year increase in da Vinci surgical procedures. Revenues from sales of systems were $225 million, up 27% year over year. The increase in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 Third Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939</link>
		<comments>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939#comments</comments>
		<pubDate>Tue, 22 Nov 2011 17:40:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86939</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported favorable third-quarter 2011 results. Earnings per share came in at $3.05, beating the Zacks Consensus Estimate of $2.76 and the year-ago figure of $2.14. Net income climbed 41.3% year over year to $122.4 million. Second Quarter Review Revenues increased 30% year over year to $446.7 million, beating the Zacks Consensus Estimate of $416 million. Instruments and accessories revenues were $175.8 million in the quarter, up 38% year over year. Worldwide procedures increased 30%. The company posted total systems revenue of $199.1 million in the quarter, up 25%. Services/Training revenues were $71.8 million in the quarter, up 25% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Agreement – Estimate Revisions Estimates for fiscal 2011 demonstrate an upward trend among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Presents Promising CyberKnife Radiosurgery Data</title>
		<link>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691</link>
		<comments>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:44:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78691</guid>
		<description><![CDATA[Leading radiosurgery systems maker Accuray Incorporated (ARAY) has presented encouraging new clinical data highlighting the benefits of its popular CyberKnife radiosurgery system and its recently acquired TomoTherapy radiation therapy system in treating a vast continuum of lung cancer patients. The data was presented at the World Conference on Lung Cancer (“WCLC”), which took place in Amsterdam, The Netherlands, between July 3 and 7, 2011. WCLC, hosted by the International Association for the Study of Lung Cancer (“IASLC”), is the leading international forum for lung cancer and thoracic oncology research and practice. IASLC is the only global organization dedicated to the study of lung cancer. The CyberKnife system delivers ablative doses of radiation to lung tumors with the highest levels of accuracy. Moreover, the TomoTherapy system delivers high quality intensity modulated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical TrueBeam Lands in Sweden</title>
		<link>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480</link>
		<comments>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:26:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78480</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical’s (VAR) coveted TrueBeam radiotherapy and radiosurgery system has made its Scandinavian debut as it was successfully placed at a leading hospital in Sweden. The advanced therapy system has begun treating cancer patients at Vasteras Hospital in Stockholm, the only hospital offering radiotherapy in Sweden. Doctors at Vasteras Hospital used the TrueBeam system to treat a 71-year old prostate cancer patient who became the first patient in Sweden to receive treatment with this novel therapy system. Prior to the arrival of the TrueBeam system, physicians at Vasteras Hospital have been treating 70 patients per day in two shifts. TrueBeam has enabled rapid treatment delivery while potentially allowing resumption of normal working patterns. Varian’s TrueBeam platform, launched in April 2010, is used in image-guided radiotherapy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical TrueBeam Makes China Debut</title>
		<link>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224</link>
		<comments>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78224</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical (VAR) has achieved another key milestone as its popular TrueBeam therapy system has been successfully deployed at Shantou University Medical College&#8217;s affiliated cancer hospital, thereby becoming the first cancer treatment center in China to install this advanced system. Shantou University Medical College is a premier medical college and health research base in southern-eastern China. The TrueBeam system was donated to the hospital by private charitable organization Li Ka Shing (“LKS”) Foundation. It was dedicated in a special ceremony held at the affiliated hospital on June 28. TrueBeam was approved in China in early 2011. Varian recently secured the Japanese regulator&#8217;s clearance for the system. Introduced in April 2010, the TrueBeam platform is used in image-guided radiotherapy and radiosurgery to treat multiple cancer types. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical Systems Wins R&amp;D 100 Award</title>
		<link>http://www.stockbloghub.com/2011/06/26/var-varian-medical-systems-wins-rd-100-award/77411</link>
		<comments>http://www.stockbloghub.com/2011/06/26/var-varian-medical-systems-wins-rd-100-award/77411#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:43:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77411</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical Systems (VAR) recently disclosed that its image guided radiotherapy and radiosurgery system (TrueBeam) is the recipient of a 2011 R&#38;D 100 Award conferred by R&#38;D Magazine. This yearly felicitation recognizes 100 technologically superior products from the previous year. R&#38;D Awards, established by the editors of R&#38;D Magazine, are given on an annual basis. This award is widely recognized as a hallmark of excellence and indicates that the product incorporates some of the most innovative thinking of the year. The TrueBeam system integrates a series of technological innovations so as to coordinate imaging, delivery of treatment, the position of the patient and his/her motion. TrueBeam also has the capability to achieve a dose delivery rate that is about twice the full output of orthodox ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/var-varian-medical-systems-wins-rd-100-award/77411/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical Systems Wins Shonin in Japan</title>
		<link>http://www.stockbloghub.com/2011/06/20/var-varian-medical-systems-wins-shonin-in-japan/76601</link>
		<comments>http://www.stockbloghub.com/2011/06/20/var-varian-medical-systems-wins-shonin-in-japan/76601#comments</comments>
		<pubDate>Mon, 20 Jun 2011 19:47:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76601</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical Systems (VAR) recently disclosed that it has won Shonin approval from the Ministry of Health, Labor and Welfare (“MHLW”) in Japan to sell its TrueBeam system for image-guided radiotherapy as well as radiosurgery. TrueBeam is Varian’s most sophisticated cancer treatment system. It is especially suitable for therapy of lung and liver cancer, which are among the five most common cancers in Japan. Varian has designed its TrueBeam system to handle tumors with precision and speed. This includes tumors that tend to move, during therapy, as the patient breathes. This cutting edge technology integrates a series of technical improvements, which provide help during treatment, such as positioning the patient and managing his/her motion. The know-how has applications in all modes of sophisticated external-beam radiotherapy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/var-varian-medical-systems-wins-shonin-in-japan/76601/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 First Quarter Earnings Beats The Street</title>
		<link>http://www.stockbloghub.com/2011/04/24/isrg-intuitive-surgical-2011-first-quarter-earnings-beats-the-street/71970</link>
		<comments>http://www.stockbloghub.com/2011/04/24/isrg-intuitive-surgical-2011-first-quarter-earnings-beats-the-street/71970#comments</comments>
		<pubDate>Mon, 25 Apr 2011 05:53:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Cardica Inc]]></category>
		<category><![CDATA[CRDC]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71970</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported first-quarter fiscal 2011 earnings per share of $2.59, outpacing the Zacks Consensus Estimate of $2.49, while surpassing the corresponding year-ago result of $2.12. Revenues Intuitive reported revenues of $388 million, up 18% year over year, exceeding the Zacks Consensus Estimate of $379 million. On a segmental basis, the company reported revenues from instruments and accessories of $157 million, up 28% year over year. The growth was driven by a 30% year-over-year increase in da Vinci surgical procedures. Revenues from sales of systems were $167 million, up 8% year over year.  Service revenue was $64 million, up 26% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Margins Intuitive Surgical experienced a drop in gross margin to 71.8% in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/24/isrg-intuitive-surgical-2011-first-quarter-earnings-beats-the-street/71970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical First Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/17/isrg-intuitive-surgical-first-quarter-2011-earnings-preview/71658</link>
		<comments>http://www.stockbloghub.com/2011/04/17/isrg-intuitive-surgical-first-quarter-2011-earnings-preview/71658#comments</comments>
		<pubDate>Mon, 18 Apr 2011 04:58:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Cardica Inc]]></category>
		<category><![CDATA[CRDC]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71658</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) is slated to report its first-quarter 2011 results on Tuesday, April 19, 2011. The current Zacks Consensus Estimate for the quarter is $2.49, representing an estimated 17.28% annualized growth. Fourth Quarter Recap Intuitive reported fourth quarter and fiscal 2010 earnings per share of $3.02 and $9.47, respectively, beating the Zacks Consensus Estimates of $2.26 and $8.71, respectively. Revenues of $389 million and $1,413 million for the fourth quarter and fiscal 2010, respectively, were up 21% and 34% year over year. The results beat the corresponding Zacks Consensus Estimates of $372 million and $1,398 million. Recurring revenues grew at a brisk pace and constituted just over one-half of sales in fiscal 2010. Instruments and accessories revenues were $151 million in the quarter, up 33% year over year. Worldwide ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/17/isrg-intuitive-surgical-first-quarter-2011-earnings-preview/71658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/04/04/aray-accuray-incorporated-bull-of-the-day/70583</link>
		<comments>http://www.stockbloghub.com/2011/04/04/aray-accuray-incorporated-bull-of-the-day/70583#comments</comments>
		<pubDate>Mon, 04 Apr 2011 13:46:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70583</guid>
		<description><![CDATA[We upgrade our recommendation on Accuray Inc. (ARAY) to Outperform following our assessment of its healthy second-quarter fiscal 2011 results and increased visibility on the stock. Earnings per share of $0.07 comfortably beat the Zacks Consensus Estimate of a loss of $0.02. The company swung to profit in the quarter as a decline in operating expenses offset lower revenues. Accuray continues to enjoy strong demand for its CyberKnife robotic radiosurgery as reflected by increasing number of patients treated with the system. Moreover, the company is expected to benefit from the recent recovery in hospital capital spending. We are also upbeat about the compelling prospect in radiation oncology rendered by the company&#8217;s impending acquisition of rival TomoTherapy. ACCURAY INC (ARAY): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/aray-accuray-incorporated-bull-of-the-day/70583/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Analyst Lifts Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/04/03/aray-accuray-analyst-lifts-shares-to-outperform/70472</link>
		<comments>http://www.stockbloghub.com/2011/04/03/aray-accuray-analyst-lifts-shares-to-outperform/70472#comments</comments>
		<pubDate>Mon, 04 Apr 2011 03:32:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70472</guid>
		<description><![CDATA[We upgrade our recommendation on Accuray Incorporated (ARAY) to Outperform following our assessment of its healthy second-quarter fiscal 2011 results and increased visibility on the stock. We are upbeat about the compelling prospect in radiation oncology rendered by the company’s impending acquisition of rival TomoTherapy (TOMO). Second quarter earnings per share of 7 cents comfortably beat the Zacks Consensus Estimate of a loss of 2 cents. The company swung to profit in the quarter as a decline in operating expenses offset lower revenues. Revenues declined 5% year over year to $54.2 million, but beat the Zacks Consensus Estimate of $49 million. The California-based company has once again backed its revenue outlook for fiscal 2011. Accuray is a global leader in the field of radiosurgery and provides a non-surgical treatment option ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/03/aray-accuray-analyst-lifts-shares-to-outperform/70472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook &#8211; April 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413</link>
		<comments>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413#comments</comments>
		<pubDate>Thu, 31 Mar 2011 23:07:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70413</guid>
		<description><![CDATA[Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this year due to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest medical devices market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AHD) Company News for March 08, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/08/ahd-company-news-for-march-08-2011-corporate-summary/68267</link>
		<comments>http://www.stockbloghub.com/2011/03/08/ahd-company-news-for-march-08-2011-corporate-summary/68267#comments</comments>
		<pubDate>Wed, 09 Mar 2011 00:57:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil & Gas Drilling & Exploration]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[AHD]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Atlas Pipeline Holdings LP]]></category>
		<category><![CDATA[Brinker International Inc.]]></category>
		<category><![CDATA[CIEN]]></category>
		<category><![CDATA[Ciena Corporation]]></category>
		<category><![CDATA[EAT]]></category>
		<category><![CDATA[HIT]]></category>
		<category><![CDATA[Hitachi Limited]]></category>
		<category><![CDATA[James River Coal Company]]></category>
		<category><![CDATA[JRCC]]></category>
		<category><![CDATA[Monster Worldwide Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MWW]]></category>
		<category><![CDATA[Repligen Corporation]]></category>
		<category><![CDATA[RGEN]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Urban Outfitters Inc.]]></category>
		<category><![CDATA[URBN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68267</guid>
		<description><![CDATA[• Ciena Corp. (NASDAQ:CIEN) reported a Q1 loss of $0.14 per share, lower than the Zacks Consensus Estimate of a loss of $0.30 per share • Urban Outfitters (NASDAQ:URBN) reported Q4 EPS of $0.45, lower than the Zacks Consensus Estimate of $0.52 per share. Revenues for the quarter rose 14% year-over-year to $668.4 million, missing the Zacks Consensus Estimate of $674.0 million • James River Coal Co (NASDAQ:JRCC) reported plans to buy International Resource Partners from Atlas Energy LP (NYSE:AHD) for $475 million in cash. The deal will help James River to increase its production and shipments of metallurgical coal • Radiosurgery firm Accuray Inc (NASDAQ:ARAY) announced that it would buy TomoTherapy Inc (NASDAQ:TOMO), a provider of advanced radiation-therapy solutions for $277 million, or $4.80 a share, in cash and stock • Computer hard-drive maker ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/08/ahd-company-news-for-march-08-2011-corporate-summary/68267/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray&#8217;s CyberKnife Reaches 100,000 Patients Treated</title>
		<link>http://www.stockbloghub.com/2010/10/11/aray-accurays-cyberknife-reaches-100000-patients-treated/54594</link>
		<comments>http://www.stockbloghub.com/2010/10/11/aray-accurays-cyberknife-reaches-100000-patients-treated/54594#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:23:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54594</guid>
		<description><![CDATA[Leading radiosurgery systems maker Accuray Incorporated (ARAY) has achieved an important milestone as patients treated with its CyberKnife robotic radiosurgery system have reportedly reached the 100,000 mark. CyberKnife is a non-invasive alternative to traditional surgery and is the only commercially available intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body. Patients can be treated with CyberKnife without anesthesia and without the risks and complications inherent in traditional surgery. The CyberKnife system combines continuous image-guidance technology with a compact linear accelerator that has the ability to move in three dimensions according to the treatment plan. The CyberKnife procedure is well tolerated. Patients do not require substantial pre-treatment preparation, and typically there is little to no recovery time or hospital stay necessary for the CyberKnife procedure. All these ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/aray-accurays-cyberknife-reaches-100000-patients-treated/54594/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Beats Earnings Estimate by 60%</title>
		<link>http://www.stockbloghub.com/2010/09/14/aray-accuray-beats-earnings-estimate-by-60/50103</link>
		<comments>http://www.stockbloghub.com/2010/09/14/aray-accuray-beats-earnings-estimate-by-60/50103#comments</comments>
		<pubDate>Tue, 14 Sep 2010 20:32:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50103</guid>
		<description><![CDATA[Accuray Inc. (ARAY), a global leader in the field of radiosurgery, reported fourth-quarter fiscal 2010 (ended June 30) earnings per share of 8 cents, exceeding the Zacks Consensus Estimate of 5 cent and the year-ago earnings of 2 cents. Net income for the quarter quadrupled year-over-year to $5 million on the back of higher product sales and the company&#8217;s cost-cutting initiatives. For fiscal 2010, net income surged to $2.8 million from $0.6 million a year-ago with earnings per share of 5 cents topping the Zacks Consensus Estimate of 1 cent. However, the California-based cancer surgery system maker released a tepid outlook for fiscal 2011, sending its shares down more than 3.5% to $6.32 in early morning trade, as the market appears to be discounting the better-than-expected results and focusing instead ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/14/aray-accuray-beats-earnings-estimate-by-60/50103/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/05/18/aray-accuray-analyst-maintains-neutral-rating/37534</link>
		<comments>http://www.stockbloghub.com/2010/05/18/aray-accuray-analyst-maintains-neutral-rating/37534#comments</comments>
		<pubDate>Tue, 18 May 2010 15:36:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37534</guid>
		<description><![CDATA[We recently reiterated our ‘Neutral’ rating on Accuray Incorporated (ARAY) with a target price of $6.75 based on a P/E of 33.8x our fiscal 2011 EPS estimate of 20 cents. The company’s results for the third quarter fiscal 2010 were mixed. Earnings per share of 4 cents were considerably higher than the Zacks Consensus Estimate of 1 cent.  However, earnings were lower than 5 cents, compared with a year-ago. Total revenues in the third quarter declined 15.3% year over year to $51.9 million. Lower revenues were due to decreased demand for the company’s CyberKnife Robotic Radiosurgery Systems. The company installed six new systems in the third quarter, versus eleven in the prior quarter. Furthermore, Accuray bagged fourteen orders for its CyberKnife Robotic Radiosurgery Systems in the third quarter, compared with eighteen in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/18/aray-accuray-analyst-maintains-neutral-rating/37534/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray&#8217;s Quarterly Earnings Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/05/09/aray-accurays-quarterly-earnings-beats-consensus-estimates/36588</link>
		<comments>http://www.stockbloghub.com/2010/05/09/aray-accurays-quarterly-earnings-beats-consensus-estimates/36588#comments</comments>
		<pubDate>Mon, 10 May 2010 05:30:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36588</guid>
		<description><![CDATA[Accuray Inc. (ARAY) reported fiscal third-quarter earnings per share of 4 cents, beating the Zacks Consensus Estimate of 1 cent and the year-ago earnings of 2 cents. Sales Total revenues in the third quarter declined 15.3% year over year to $51.9 million. Lower revenues can be attributed to lower demand for the company’s CyberKnife Robotic Radiosurgery Systems. The company installed six new systems in the third quarter, versus eleven in the prior quarter. Furthermore, Accuray bagged fourteen orders for its CyberKnife Robotic Radiosurgery Systems in the third quarter, compared to eighteen in the prior quarter. Product revenues declined 17.6% year over year to roughly $33.8 million. Services revenues declined 2.0% year over year to $17.5 million. Margins Gross margin declined 60 basis points (bps) year over year to 48.9%. Selling ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/09/aray-accurays-quarterly-earnings-beats-consensus-estimates/36588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Upgraded to Neutral by Analysts</title>
		<link>http://www.stockbloghub.com/2010/02/15/aray-accuray-upgraded-to-neutral-by-analysts/28006</link>
		<comments>http://www.stockbloghub.com/2010/02/15/aray-accuray-upgraded-to-neutral-by-analysts/28006#comments</comments>
		<pubDate>Mon, 15 Feb 2010 23:23:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28006</guid>
		<description><![CDATA[We recently upgraded Accuray Inc. (ARAY) to Neutral. The stock was assigned a target price of $7.50 based on a P/S of 1.8x our fiscal 2011 sales estimate of $236 million. Accuray reported a second quarter fiscal 2010 loss per share of 2 cents, wider than the Zacks Consensus Estimate of a loss per share of 1 cent. However, the company had reported earnings per share of 2 cents in the year-ago quarter. Total revenues in the second quarter declined roughly 0.5% year over year to $57.3 million. Products revenues declined approximately 13.6% year over year to $35.7 million. Accuray bagged 18 orders for its CyberKnife Robotic Radiosurgery Systems and installed 11 new systems in the second quarter. Headquartered in Sunnyvale, California, Accuray Incorporated designs, develops, and sells the CyberKnife ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/15/aray-accuray-upgraded-to-neutral-by-analysts/28006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Incorporated Disappoints</title>
		<link>http://www.stockbloghub.com/2010/02/05/aray-accuray-incorporated-disappoints/27166</link>
		<comments>http://www.stockbloghub.com/2010/02/05/aray-accuray-incorporated-disappoints/27166#comments</comments>
		<pubDate>Sat, 06 Feb 2010 00:59:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27166</guid>
		<description><![CDATA[Accuray Incorporated (ARAY) reported disappointing results for the second quarter of fiscal 2010. Loss per share was 2 cents, higher than the Zacks Consensus Estimate of a loss per share of 1 cent. However, Accuray reported earnings per share of 2 cents in the year-ago quarter. Sales Total revenues in the quarter declined roughly 0.5% year over year to $57.3 million. Products revenues declined approximately 13.6% year over year to $35.7 million. Accuray bagged 18 orders for its CyberKnife Robotic Radiosurgery Systems and installed 11 new systems in the reported quarter. Margins Accuray witnessed a contraction in margins in the reported quarter. Gross margin declined 570 basis points (bps) year over year to 45.3%. Selling and marketing expenses as a percentage of sales declined 100 bps year over year to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/aray-accuray-incorporated-disappoints/27166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/01/18/aray-accuray-incorporated-bear-of-the-day/25166</link>
		<comments>http://www.stockbloghub.com/2010/01/18/aray-accuray-incorporated-bear-of-the-day/25166#comments</comments>
		<pubDate>Mon, 18 Jan 2010 17:12:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25166</guid>
		<description><![CDATA[Accuray Incorporated (ARAY) designs, develops and sells the CyberKnife System, an image-guided robotic radiosurgery system used for the treatment of solid tumors. The company was badly affected by reimbursement uncertainties surrounding its products. This was reflected in Accuray&#8217;s top and bottom line performance in the first quarter of fiscal 2010. Accuray reported a net loss of $0.06 per share in the first quarter, compared to the Zacks Consensus Estimate of a net loss of $0.03 per share and unchanged from the year-ago figure. Total revenues declined 9.5% year over year in the reported quarter. We downgrade the stock to Underperform with a target price of $6. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/aray-accuray-incorporated-bear-of-the-day/25166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Incorporated is Downgraded to Underperform</title>
		<link>http://www.stockbloghub.com/2010/01/15/aray-accuray-incorporated-is-downgraded-to-underperform/25077</link>
		<comments>http://www.stockbloghub.com/2010/01/15/aray-accuray-incorporated-is-downgraded-to-underperform/25077#comments</comments>
		<pubDate>Sat, 16 Jan 2010 00:49:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25077</guid>
		<description><![CDATA[We recently downgraded Accuray Incorporated (ARAY) to Underperform with a target price of $6. Accuray reported a net loss of 6 cents per share in the first quarter of fiscal 2010, compared to the Zacks Consensus Estimate of a net loss of 3 cents per share and unchanged from the year-ago figure. Total revenues declined 9.5% year over year to $50.6 million in the reported quarter. Gross margin in the reported quarter declined 820 basis points (bps) year over year to 42.7%. Selling and marketing expenses as a percentage of sales declined 700 bps year over year to 17.1%. Research and development expenses as a percentage of sales declined 60 bps year over year to 15.1%. General and administrative expenses as a percentage of sales declined 100 bps year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/15/aray-accuray-incorporated-is-downgraded-to-underperform/25077/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Misses Forecast, Lowers Outlook</title>
		<link>http://www.stockbloghub.com/2009/08/26/aray-accuray-misses-forecast-lowers-outlook/13451</link>
		<comments>http://www.stockbloghub.com/2009/08/26/aray-accuray-misses-forecast-lowers-outlook/13451#comments</comments>
		<pubDate>Wed, 26 Aug 2009 16:12:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13451</guid>
		<description><![CDATA[Accuray Incorporated (ARAY) reported fourth quarter and full fiscal year 2009 results. Earnings per share in the fourth quarter were 2 cents, compared to the Zacks Consensus Estimate of 3 cents and the year-ago earnings that were break-even. Quarterly results Sales Total revenues in the quarter were $58.8 million Incorporatedreasing 15% year over year. Growth was primarily led by higher services revenues that increased 58% year over year to $18.6 million. Product revenues increased roughly 11% year over year to $39.5 million. The total number of CyberKnife Systems installed in the quarter was twelve, twice that in the year-ago quarter. Backlog Accuray has a practice of reporting backlog comprised of signed contracts that can generate revenues in the future. Total backlog at the end of the quarter was $556 million, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/aray-accuray-misses-forecast-lowers-outlook/13451/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PX) Current Stock Prices: Why Trillions of Dollars on the Sidelines Maybe A Good Thing</title>
		<link>http://www.stockbloghub.com/2009/02/09/px-current-stock-prices-why-trillions-of-dollars-on-the-sidelines-maybe-a-good-thing/2593</link>
		<comments>http://www.stockbloghub.com/2009/02/09/px-current-stock-prices-why-trillions-of-dollars-on-the-sidelines-maybe-a-good-thing/2593#comments</comments>
		<pubDate>Mon, 09 Feb 2009 22:49:06 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Synthetics]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[MAT]]></category>
		<category><![CDATA[Mattel Inc.]]></category>
		<category><![CDATA[Praxair Inc.]]></category>
		<category><![CDATA[PX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2593</guid>
		<description><![CDATA[by Alexander Green, Oxford Club Investment Director You can’t blame most market investors for being nervous… The stock market has done a belly flop. Real estate keeps tumbling. The economy remains weak. Jobless claims recently hit a 26-year high. Investors have pulled tens of billions of dollars out of stocks and plunked it in the bank. We are optimistic, nonetheless. Why? Because the bad news is already reflected in current stock prices. Valuations are attractive. Negative sentiment is a bullish signal, not a bearish one. And all that cash sitting on the sidelines is actually a good thing. This month we’ll look at why. We’ll also highlight a world-class biotech firm that will allow you to take advantage of one of the most attractive buying opportunities in almost two decades. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/09/px-current-stock-prices-why-trillions-of-dollars-on-the-sidelines-maybe-a-good-thing/2593/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray: Stock of the Day</title>
		<link>http://www.stockbloghub.com/2009/02/03/accuray-stock-of-the-day/2491</link>
		<comments>http://www.stockbloghub.com/2009/02/03/accuray-stock-of-the-day/2491#comments</comments>
		<pubDate>Tue, 03 Feb 2009 22:21:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2491</guid>
		<description><![CDATA[by Katharine Schildt, Assistant Editor, The Oxford Club The health care sector is about as recession-proof as you can get – quite an attractive quality in these trying times. According to some analysts health care could average a 25% gain this year. These gains are possible because our population is living longer as it grows older. That means more people suffering from harder-to-treat diseases longer. And disease’s poster-child is cancer. It claimed over 500,000 people in the United States alone last year. Cancer is one of the leading killers around the world as well. And even with recent gains in cancer treatment, the number of people suffering from this debilitating disease is expected to increase in coming years. Accuray – A Global Leader in Radiosurgery It’s what makes Accuray (Nasdaq: ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/03/accuray-stock-of-the-day/2491/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

